|
|
Article: Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008.
- Article from:
- PR Newswire
- Article date:
- July 9, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Most Surveyed MCO Pharmacy Directors Will Move Razadyne and Razadyne ER from Tier 2 to Tier 3 When Generic Razadyne is Launched, According to a New Report from Decision Resources
WALTHAM, Mass., July 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the generic availability of Shire/Janssen/Ortho McNeil's Razadyne (galantamine) in December 2008 will have the greatest impact on Eisai/Pfizer's Aricept as surveyed primary care physicians (PCPs) estimate that after the launch of generic galantamine, prescriptions of Aricept for the treatment of Alzheimer's disease will ...
Related newspaper, magazine, and journal articles:
|
|
Article: Decision Resources' Updated Rheumatoid Arthritis ...
PR Newswire;
August 6, 2009 ;
700+ words
... ... Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research ... premium-priced biologics. However, Decision Resources conservatively forecasts that fostamatinib ... 3 inhibitor CP-690550," said Decision Resources Analyst Joanna Kim, M.Ed. "Fostamatinib ...
|
|